• Skip to primary navigation
  • Skip to main content
  • Skip to footer

RAIRDA HomepageRAIRDA

The Rare Autoimmune Rheumatic Disease Alliance

  • About us
    • Our members
    • About RAIRDs
    • Our board
    • Our story
  • What we do
    • Our priorities
    • A quality standard for rare disease
    • Publications
  • News
  • Get involved
    • Personal stories
    • Share your story
    • Campaign for us
  • Contact us
  • Search

RAIRDA launches fourth vaccination dose survey

RAIRDA and its member charities have launched a short survey aimed at all adults with a rheumatic condition in the UK. We want to understand whether those who are eligible have been able to access a fourth dose of the coronavirus (COVID-19) vaccine as part of their COVID-19 vaccination schedule as well as gain insights on other important issues related to COVID-19.

To be clear this ‘fourth dose’ is a ‘booster’ dose. You can get a booster (4th dose) from 3 months (91 days) after your 3rd primary dose. Eligibility criteria for the third and fourth dose of the COVID-19 vaccine can be found via the following link: https://bit.ly/3D0m6KR

Please only complete the survey if you have a rheumatic condition AND believe yourself to be eligible for a third/fourth dose of the COVID-19 vaccine.

Examples of rheumatic conditions include:

  • Forms of connective tissue disease (for example: lupus, Sjogren’s Syndrome, scleroderma)
  • Form of systemic vasculitis (For example: Behcet’s or types of ANCA Vasculitis like GPA)
  • Giant Cell Arteritis
  • Rheumatoid arthritis
  • Psoriatic arthritis
  • Axial spondyloarthritis (including ankylosing spondyloarthritis)
  • Polymyalgia Rheumatica

This survey will close on midnight Thursday 7th April 2022.

CLICK HERE TO TAKE THE SURVEY

Share this post:

Share on Twitter Share on Facebook Share on LinkedIn Share on E-mail
More news
« Safe At Work: letter to employers, March 2022
Survey shows poor communication around COVID-19 vaccine and treatments for people with rheumatic conditions »

Footer

  • Twitter

The @APPG_VGP is calling for evidence and responses from patients, hospitals, patient groups, charities, clinicians, academics and private companies, to look at the experience of the #Forgotten500k immunocompromised patients during the pandemic. appg-vulnerablegroups.org/new…

GIRFT has worked with RAIRDA to develop the pathways for Giant Cell Arteritis (GCA) and Connective Tissue Disease. All 4 pathways support clinicians to provide the best patient care, and allow patients and commissioners to see what they can expect from a service. twitter.com/NHSGIRFT/statu…

It's great to see RAIRDA's policy paper and the stories of people with RAIRDs receive coverage in Personnel Today, the Daily Express, the Daily Record and the Daily Mirror today. personneltoday.com/hr/call-to…

RAIRDA have produced a Q&A document to address misconceptions and common questions about COVID vaccinations for people with RAIRDs. rairda.org/vaccines-misco…

Despite visiting her GP on several occasions, it took Georgina over 18 months to reach a diagnosis. We urgently need a quicker and more effective diagnostic journey for people with RAIRDs.#RAIRDA #ResettingtheBalance rairda.org/resetting-the-…

Contact us